Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future

Table 2 Key studies of TNF-blocker therapy in psoriatic arthritis

				Outcomes reported
							Dactylitis		Function
Therapy	Published study	Primary outcome	Radiologic outcomes	Joint	Skin	Nail		Enthesitis		QoL	Pain	EMS	Fatigue	CRP/ ESR
Infliximab	Antoni and colleagues [59], Kavanaugh and colleagues [52]	ACR20 at week 16	mvdH-SS at week 50	x	x		x	x	x		x			x
Infliximab	Antoni and colleagues [60], van der Heijde and colleagues [56]	ACR20 at week 14	mvdH-SS at weeks 24 and 54	x	x		x	x	x		x	x		x
Etanercept	Mease and colleagues [61]	PsARC at week 12	NA	x	x				x		x			x
Etanercept	Mease and colleagues [58]	ACR20 at week 12	mTSS at months 6 and 12	x	x				x		x			x
Adalimumab	Mease and colleagues [54]	ACR20 at week 12	mTSS at week 24	x	x		x	x	x	x			x
Golimumab	Kavanaugh and colleagues [62]	ACR20 at week 14	NA	x	x	x	x	x	x

ACR20, American College of Rheumatology 20% improvement; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate, EMS, early morning stiffness; mvdH-SS, modified van der Heijde–Sharp score; mTSS, modified total Sharp score; NA, not available; PsARC, Psoriasis Arthritis Response Criteria; QoL, quality of life.

ISSN: 1478-6362